Jungla

What Jungla does

Jungla Inc. was a South San Francisco-based biotechnology company founded in 2016 by three Stanford PhDs (Carlos Araya, Alex Colavin, Jason Reuter) that developed the Molecular Evidence Platform (MEP), an active learning engine for clinical genetic variant interpretation. The MEP combined large-scale functional genomics (wet lab methods) with computational biophysics and integrative computational modeling (dry lab methods) to systematically generate, evaluate, audit, and distribute evidence models evaluating how genetic variants impact molecular, cellular, and evolutionary processes. The platform addressed the core problem that less than 1% of genetic variants in the human population are clinically understood, providing robust, quantitative, and transparent clinical guidance for molecular diagnostic and screening tests as well as therapeutic interventions. Disclosed performance metrics included >=95% prospective accuracy (exceeding ACMG/AMP recommendations), coverage of over 100,000 molecular variants at ~85% completeness, and support for hundreds of genes and conditions.

The company served three primary customer segments through a B2B enterprise partnership model: leading clinical laboratories seeking enhanced functional evidence for variant interpretation (primary segment), pharmaceutical companies requiring variant interpretation for drug development and personalized medicine, and IT firms building precision medicine infrastructure. Revenue was generated through subscription/recurring platform licensing and partnership services distributed via direct enterprise engagements, with inquiries managed through dedicated email channels rather than traditional sales motions. Jungla raised approximately $2.8M in total disclosed venture funding (a $250K seed from SOSV/IndieBio in March 2016 and a $2.55M Series A led by Andreessen Horowitz in November 2016) and maintained a lean team of 1-10 employees. In July 2019, Invitae Corporation acquired Jungla for approximately $65 million to extend its variant interpretation capabilities with supplemental RNA analysis, ending Jungla's independent operations.

Name

Jungla

Legal name

Jungla Inc.

Website

https://jungla.bio

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

1–10 employees

Short description

Jungla Inc. was a Stanford-founded biotechnology company (2016-2019) that built the Molecular Evidence Platform, an active learning engine integrating functional genomics and computational biophysics to interpret clinical genetic variants for clinical laboratories, pharmaceutical companies, and healthtech firms.

Ownership category

akta.pro rank

Product category

Clinical Genomics Software

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Genetic variant interpretation
• Clinical genomics platform
• Precision medicine infrastructure
• Functional genomics analysis
• Molecular diagnostic evidence

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Platform Licensing and Partnership Services: B2B revenue model through partnerships with clinical laboratories, pharmaceutical companies, and IT firms. The company provides its Molecular Evidence Platform as infrastructure to enhance precision medicine capabilities of partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Jungla developed and sold the Molecular Evidence Platform (MEP), an active learning engine that integrates functional genomics and computational biophysics to systematically generate, evaluate, audit, and distribute evidence models for clinical genetic variant interpretation. The platform enabled clinical laboratories, pharmaceutical companies, and IT firms to deliver robust, quantitative, and transparent clinical guidance for molecular diagnostic tests, screening tests, and therapeutic interventions, addressing the gap that less than 1% of genetic variants are clinically understood.

Product overview

Jungla offers a single unified product—the Molecular Evidence Platform (MEP)—which provides variant interpretation solutions for clinical genetic and genomic testing. The MEP is an active learning engine that continuously integrates and enhances clinical knowledge with functional and computational evidence, systematically generating, evaluating, and auditing evidence models. The platform delivers robust, quantitative, and transparent clinical guidance with demonstrated prospective accuracy exceeding 95%, covering over 100,000 molecular variants across hundreds of genes and conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Molecular Evidence Platform (MEP)
• Variant Interpretation Solutions Solutions that augment and optimize guidance in clinical genetic and genomic tests, enabling clinicians to look deeper into genomes to overcome uncertainty in clinical interpretation where less than 1% of genetic variants are clinically understood. Delivered to clinical laboratories and partners as part of the Molecular Evidence Platform offering.

Quantifiable outcome

• >=95% Prospective Accuracy exceeds ACMG/AMP recommendations
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Invitae CorporationcoreStrategic or Co-development Partner · 1 July 2019Invitae Corporation announced acquisition of Jungla Inc. in July 2019. This acquisition was intended to advance genetic variant interpretation and add supplemental RNA analysis capabilities to deliver deeper, more informative results to patients.
• Hewlett Packard EnterprisecoreStrategic or Co-development Partner · 27 November 2018HPE partnered with Jungla through Tech Impact 2030 initiative to advance precision medicine using memory-driven computing. The partnership demonstrated memory-driven improvements in high-resolution molecular analyses, achieving >200x faster compute time (0.4% of original compute time). Jungla was featured in 'Reimagining Medical Testing' and 'The Future of AI' platform sessions at HPE Discover 2018.
• JLABS / Johnson & Johnson InnovationminorStrategic or Co-development Partner · 1 November 2018Jungla was selected for participation as one of JLABS HealthTech startups at the NYC program in November 2018, gaining access to Johnson & Johnson Innovation ecosystem.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Fabric Genomics: Fabric Genomics builds AI-driven clinical genomics interpretation platforms for rare disease and oncology diagnostics. It is the most direct peer to Jungla, operating a software platform that ingests sequencing data and produces ranked, clinically-actionable variant calls for hospital and lab customers.
• Sophia Genetics: Sophia Genetics combines AI with multimodal clinical and genomic data to support diagnosis and treatment decisions across hospital systems. It directly overlaps Jungla's positioning as an AI platform that translates complex genomic inputs into standardized, clinically-actionable outputs for healthcare providers.

Others

• DNAnexus: DNAnexus operates a cloud-based genomics data platform used by clinical labs and pharma for sequencing data management and analysis pipelines. It is an enabling/infrastructure peer that complements rather than directly competes with Jungla's interpretation layer.

Broad incumbents

• Illumina: Illumina is the dominant sequencing platform provider and increasingly offers downstream interpretation and clinical informatics solutions (e.g., Illumina Connected Analytics, TruSight). It is a broad incumbent that influences the variant interpretation ecosystem Jungla operates in.
• Color Genomics: Color provides population-scale genetic testing across hereditary cancer, cardiovascular, and pharmacogenomics. While more consumer-facing than Jungla, it relies on the same variant interpretation pipelines and competes for clinical variant interpretation partnerships.
• GeneDx: GeneDx is a major clinical genomics lab providing rare disease, hereditary cancer, and whole-exome interpretation at scale. It is a broad incumbent customer/prospect for variant interpretation technology comparable to Jungla's Molecular Evidence Platform.
• Ambry Genetics: Ambry Genetics is a clinical genetic testing laboratory with deep expertise in hereditary cancer and rare disease variant interpretation. It represents a potential enterprise customer profile similar to Jungla's clinical laboratory segment.
• Invitae Corporation: Invitae is a large clinical genetics testing company that acquired Jungla in 2019. Beyond the acquisition relationship, Invitae is a broad incumbent serving clinical variant interpretation needs at scale, overlapping with Jungla's core use case of providing variant interpretation to clinical labs and providers.

Emerging players

• Deep Genomics: Deep Genomics applies machine learning to identify novel genetic targets and predict variant effects on RNA biology. It overlaps Jungla's core competency in computational prediction of variant functional impact, although Deep Genomics is more therapeutics-development oriented.

Regional players

• BC Platforms: BC Platforms provides genomic data management and analytics platforms primarily in Europe, with comparable offerings to Jungla in clinical variant interpretation. It is a regional peer with similar underlying technology approach but different geographic focus.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/junglainc
• LinkedInlinkedin.com/company/7797563

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jungla